Incretin receptors explained: GLP-1, GIP and glucagon

Terms like GLP-1, GIP and glucagon appear constantly in metabolic peptide research, often bundled together as "incretin pathways." They are related but distinct. Understanding what each receptor does is the key to reading the whole field — from single-pathway analogues to triple agonists.

What an incretin is

Incretins are hormones the gut releases after food to help the body manage the incoming nutrients. Two dominate the research literature: GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). Each acts on its own receptor and is studied for a distinct role in how glucose and appetite are regulated in laboratory models.

The GLP-1 receptor

The GLP-1 receptor is the most studied of the group. In research models it is examined for its role in glucose-dependent insulin signalling, in slowing gastric emptying, and in satiety pathways in the brain. It is the target of the single-pathway analogues — our article on semaglutide covers the archetype.

The GIP receptor

GIP works through a separate receptor but overlaps with GLP-1 in glucose regulation. Its independent role is why compounds that engage both receptors at once — dual agonists such as tirzepatide — became a distinct research direction, studied for stronger effects on metabolic markers than either pathway alone.

The glucagon receptor

Glucagon is often thought of as insulin's counterpart, but its receptor is studied for a further role: influencing energy expenditure in laboratory models. Adding glucagon-receptor activity is what defines the triple agonists, such as retatrutide. Our article on GLP-1 analogues compares the single, dual and triple approaches side by side.

Why the distinctions matter

Reading peptide research means knowing which receptors a molecule engages. A single-, dual- or triple-pathway design behaves differently in study models, and the receptor map above is the framework that makes those differences legible.